ÂÜÀòÂÒÂ×

Mr. Pearson was appointed CEO of Carrick in July 2019. Most recently he served as Executive Vice President and Chief Financial Officer for TESARO Inc., a publicly held oncology-focused biopharmaceutical company, since 2014. While at TESARO, Mr. Pearson successfully raised over $1.6bn in funding, and helped build the company from 60 to over 850 people before the sale to GSK in January of 2019 for $5bn. His leadership helped TESARO gain regulatory approval and commercialize two cancer drugs in the U.S. and Europe. Prior to that, he was Executive Vice President and Chief Financial Officer at Catalyst Health Solutions, a publicly traded pharmacy benefit manager with over $5 bn in revenues until the company was acquired by SXC Health Solutions (now part of United Healthcare) in 2012. Prior to Catalyst, Mr. Pearson worked for MedImmune in various finance roles from 1998 through its sale to AstraZeneca in 2007 for $16bn. He continued employment with MedImmune after the acquisition through 2011 as Executive Vice President and Chief Financial Officer where he had functional responsibility for finance, information technology, and strategic planning.

In addition to Carrick’s board of directors, Mr. Pearson leverages his passion for improving the lives of patients with critical diseases by serving as Chairman of GlycoMimetics, Inc. and is on the Board of Ra Pharmaceutical Inc. Mr. Pearson, a CPA, holds a B.S. in Business Administration from the University of Delaware, a B.S. in Accounting from the University of Maryland University College, and an M.S. in Finance from Loyola University.